Teva Pharmaceutical Industries Quarterly Balance Sheet
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Teva Pharmaceutical Industries financial position
As of Jun 30, 2026, Teva Pharmaceutical Industries reported total assets of $39.86 billion, down 0.7% from a year earlier against total liabilities of $32.10 billion. Shareholders' equity stood at $7.75 billion, or 19.5% of assets. The company held $3.65 billion in cash and equivalents against $4.50 billion of debt, a net debt position of $845.0 million.
The current ratio (current assets divided by current liabilities) was 0.88, meaning short-term obligations exceed short-term assets. Debt-to-equity was 0.58.
Summary generated from market data by MetaCap's automated system. Methodology
Teva Pharmaceutical Industries balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.65B | 3.74B | 3.56B | 2.20B | 2.16B | 1.70B | 3.30B | 3.32B | 2.26B | 2.99B | 3.23B | 2.25B |
| Receivables | 3.49B | 3.39B | 3.71B | 3.81B | 3.56B | 3.38B | 3.06B | 3.46B | 3.77B | 3.46B | 3.41B | 3.38B |
| Inventory | 3.22B | 3.18B | 3.18B | 3.32B | 3.50B | 3.25B | 3.01B | 3.96B | 3.93B | 3.95B | 4.02B | 4.05B |
| Total Current Assets | 13.76B | 13.71B | 13.95B | 12.74B | 12.62B | 11.53B | 12.55B | 12.31B | 11.63B | 12.30B | 12.48B | 11.43B |
| Property, Plant & Equipment | 3.93B | 4.00B | 4.08B | 4.82B | 4.81B | 4.63B | 4.58B | 5.67B | 5.57B | 5.62B | 5.75B | 5.62B |
| Goodwill | 15.84B | 15.82B | 16.00B | 15.95B | 15.95B | 15.48B | 16.00B | 16.12B | 16.49B | 17.01B | 17.18B | 16.89B |
| Intangible Assets | 3.45B | 3.61B | 3.78B | 3.94B | 4.14B | 4.19B | 4.42B | 4.76B | 4.85B | 5.06B | 5.39B | 5.53B |
| Total Assets | 39.86B | 40.04B | 40.75B | 39.86B | 40.13B | 38.41B | 39.33B | 41.76B | 41.34B | 42.77B | 43.48B | 42.09B |
| Accounts Payable | 2.72B | 2.60B | 225.00M | 2.35B | 2.50B | 2.29B | 158.00M | 2.37B | 2.37B | 2.44B | 108.00M | 2.28B |
| Short-Term Debt | 4.50B | 2.61B | 1.82B | 24.00M | 464.00M | 421.00M | 1.78B | 2.58B | 2.09B | 3.06B | 1.67B | 1.48B |
| Total Current Liabilities | 15.65B | 13.53B | 13.46B | 11.49B | 11.86B | 11.16B | 12.80B | 13.80B | 13.04B | 13.79B | 12.25B | 11.39B |
| Total Liabilities | 32.10B | 31.81B | 32.83B | 32.60B | 33.30B | 32.15B | 33.61B | 35.38B | 34.77B | 35.23B | 35.35B | 34.71B |
| Shareholders' Equity | 7.75B | 8.23B | 7.91B | 7.25B | 6.83B | 6.26B | 5.37B | 6.07B | 6.36B | 7.28B | 7.51B | 6.93B |
| Retained Earnings | -13.97B | -13.39B | -13.76B | -14.24B | -14.68B | -14.96B | -15.17B | -14.96B | -14.52B | -13.67B | -13.53B | -13.99B |
| Total Debt | 4.50B | 2.61B | 1.82B | 24.00M | 464.00M | 421.00M | 1.78B | 2.58B | 2.09B | 3.06B | 1.67B | 1.48B |
| Net Cash (Debt) | -845.00M | 1.13B | 1.74B | 2.18B | 1.70B | 1.28B | 1.52B | 739.00M | 164.00M | -69.00M | 1.55B | 770.00M |
This table shows 12 quarterly periods of Teva Pharmaceutical Industries's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TEVA's reporting calendar. What is a balance sheet?